Epidermal growth factor receptor and G250: Useful target antigens for antibody mediated cellular cytotoxicity against renal cell carcinoma?

Journal of Urology

Volumn 167, Issue 2 I, 2002, Pages 707-712

  Stadick, H ^a   Stockmeyer, B ^a   Kuhn, R ^a   Schrott, K M ^a   Kalden, J R ^a   Glennie, M J ^a   Van de Winkel, J G J ^a   Gramatzki, M ^a   Valerius, T ^a   Elsasser D ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Antibody dependent cell cytotoxicity; Carcinoma, renal call; Immunotherapy; Kidney; Receptors, Fc

Indexed keywords

BISPECIFIC ANTIBODY; CHROMIUM 51; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FC RECEPTOR; G250 ANTIBODY; G250 ANTIGEN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER CELL DESTRUCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CROSS LINKING; DRUG EFFECT; DRUG EFFICACY; EFFECTOR CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; MONONUCLEAR CELL; PRIORITY JOURNAL;

EID: 0036143576     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)69131-6     Document Type: Article

References (34)

1. Systemic therapy for renal cell carcinoma
2. Unconjugated monoclonal antibodies for the treatment of hematologic and solid malignancies
3. An overview of monoclonal antibody therapy of cancer
4. Monoclonal antibodies in urologic oncology
5. The use of monoclonal antibody G250 in the therapy of renal cell carcinoma
6. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy
7. Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250
8. 131I- labeled chimeric monoclonal antibody G250
9. Phase II study of anti-epidermal growth factor receptor antibody C225 alone in patients with metastatic renal cell carcinoma
10. Monoclonal antibody therapies-a 'constant' threat to cancer
11. Fc receptors are required in passive and active immunity to melanoma
12. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets
13. Preclinical and clinical data with bispecific antibodies recruiting myeloid effector cells for tumor therapy
14. Triggering Fcα-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy
15. Bispecific antibodies in cancer therapy
16. Immunotherapeutic perspective for bispecific antibodies
17. Phase II trial of the bispecific antibody MDX-H210 [anti-HER-2/neu × anti-CD64] combined with GM-CSF in patients with advanced prostate and renal cell carcinomas that express HER-2/neu
18. A phase I trial of the epidermal growth factor receptor- directed bispecific antibody MDX-447 in patients with solid tumors
19. Establishment and characterization of human renal cancer and normal kidney cell lines
20. Humanization of a mouse monoclonal antibody by CDR-grafting: The importance of framework residues on loop conformation
21. Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney
22. 2 antibody containing thioether-linked Fab'γ fragments
23. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice
24. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy
25. Therapeutic effects of monoclonal antibody G250, interferons and tumor necrosis factor, in mice with renal-cell carcinoma xenografts
26. Antibody localization in human renal cell carcinoma: A phase I study of monoclonal antibody G250
27. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
28. Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma
29. Preclinical studies combining bispecific antibodies with cytokine-stimulated effector cells for immunotherapy of renal cell carcinoma
30. Structure and function of human IgA Fc receptors (FcαR)
31. Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies
32. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (I+II)
33. Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor
34. Therapeutic efficacy of FcγRI/CD64-directed bispecific antibodies in B-cell lymphoma